BLCA-4在膀胱癌中作用的研究进展

近年来,膀胱癌的发病率与死亡率呈逐年上升,已成为泌尿系统最常见的肿瘤。随着分子生物技术的不断发展,核基质蛋白（SMVs）、膀胱肿瘤抗原（BTA）、透明质酸和透明质酸酶（HA—Haase）、细胞角蛋O（CK）等诸多膀胱肿瘤标志物被发现。其中,膀胱癌特异性核基质蛋白-4（BLCA-4）是一种可溶性的复合物,在正常膀胱组织中不表达而存在于膀胱癌组织中。检测尿样中BLCA-4水平有望用于膀胱癌的筛查及诊断,具有较高的敏感性和特异性,也可用于普通人群与膀胱癌高危人群（脊髓损伤患者）的筛选与检测;而术后病理组织检测BLCA-4的表达也可为膀胱癌患者的预后预测提供参考。本文对近年来BLCA-4在膀胱癌中的作用进行了综述。     

BLCA-4 在膀胱癌中作用的研究进展

摘要：近年来,膀胱癌的发病率与死亡率呈逐年上升,已成为泌尿系统最常见的肿瘤。随着分子生物技术的不断发展,核基质蛋白 (NMPs)、膀胱肿瘤抗原(BTA)、透明质酸和透明质酸酶(HA-HAase)、细胞角蛋白(CK)等诸多膀胱肿瘤标志物被发现。其中,膀胱癌 特异性核基质蛋白-4(BLCA-4)是一种可溶性的复合物,在正常膀胱组织中不表达而存在于膀胱癌组织中。检测尿样中BLCA-4 水平有望用于膀胱癌的筛查及诊断,具有较高的敏感性和特异性,也可用于普通人群与膀胱癌高危人群(脊髓损伤患者)的筛选与 检测;而术后病理组织检测BLCA-4 的表达也可为膀胱癌患者的预后预测提供参考。本文对近年来BLCA-4 在膀胱癌中的作用进 行了综述。     

DNA甲基化与膀胱癌的研究进展

DNA甲基化与膀胱癌的发生有密切的关系,是抑癌基因失活的一个重要方式,有可能成为膀胱癌诊断的分子标志物.去甲基化有望成为膀胱癌治疗新方法.同时甲基化分析技术发展迅速,包括寡核苷酸探针微阵列在内的甲基化芯片技术已成为目前甲基化检测的主要方法.本文就其相关进展进行综述.     

Oncogenic miRNA-182-5p Targets Smad4 and RECK in Human Bladder Cancer

Onco-miR-182-5p has been reported to be over-expressed in bladder cancer (BC) tissues however a detailed functional analysis of miR-182-5p has not been carried out in BC. Therefore the purpose of this study was to: 1. conduct a functional analysis of miR-182-5p in bladder cancer, 2. assess its usefulness as a tumor marker, 3. identify miR-182-5p target genes in BC. Initially we found that miR-182-5p expression was significantly higher in bladder cancer compared to normal tissues and high miR-182-5p expression was associated with shorter overall survival in BC patients. To study the functional significance of miR-182-5p, we over-expressed miR-182-5p with miR-182-5p precursor and observed that cell proliferation, migration and invasion abilities were increased in BC cells. However cell apoptosis was inhibited by miR-182-5p. We also identified Smad4 and RECK as potential target genes of miR-182-5p using several algorithms. 3′UTR luciferase activity of these target genes was significantly decreased and protein expression of these target genes was significantly up-regulated in miR-182-5p inhibitor transfected bladder cancer cells. MiR-182-5p also increased nuclear beta-catenin expression and while Smad4 repressed nuclear beta-catenin expression. In conclusion, our data suggests that miR-182-5p plays an important role as an oncogene by knocking down RECK and Smad4, resulting in activation of the Wnt-beta-catenin signaling pathway in bladder cancer.     

Human Insulin Does Not Increase Bladder Cancer Risk

Background

Whether human insulin can induce bladder cancer is rarely studied.

Methods

The reimbursement databases of all Taiwanese diabetic patients from 1996 to 2009 were retrieved from the National Health Insurance. An entry date was set at 1 January 2004 and a total of 785,234 patients with type 2 diabetes were followed up for bladder cancer incidence until the end of 2009. Users of pioglitazone were excluded and the period since the initiation of insulin glargine (marketed after the entry date in Taiwan) was not included in the calculation of follow-up. Incidences for ever-users, never-users and subgroups of human insulin exposure (using tertile cutoffs of time since starting insulin, duration of therapy and cumulative dose) were calculated and the hazard ratios were estimated by Cox regression.

Results

There were 87,940 ever-users and 697,294 never-users, with respective numbers of incident bladder cancer of 454 (0.52%) and 3,330 (0.48%), and respective incidence of 120.49 and 94.74 per 100,000 person-years. The overall hazard ratios (95% confidence intervals) indicated a significant association with insulin in the age-sex-adjusted models [1.238 (1.122–1.366)], but not in the model adjusted for all covariates [1.063 (0.951–1.187)]. There was also a significant trend for the hazard ratios for the different categories of the dose-response parameters in the age-sex-adjusted models, which became insignificant when all covariates were adjusted.

Conclusions

This study relieves the concern of a bladder cancer risk associated with human insulin. Appropriate adjustment for confounders is important in the evaluation of cancer risk associated with a medication.     

人膀胱癌中某些癌基因的研究

本实验应用Northern和斑点印渍杂交技术探测了人膀胱癌细胞株中c-myc、c-fos、erbB等癌基因的表达,以及TPA对这些癌基因表达的调控,发现BIU-87细胞有这些癌基因的表达,并能被TPA所增强,同时也发现人膀胱癌组织有c-myc、c-fos、erbB、N-ras基因的高表达。提示蛋白激酶C的激活可以诱导某些癌基因的表达。多种癌基因的表达异常可能在膀胱癌中起重要作用。     

高强度聚焦超声对人膀胱癌细胞的生长抑制作用及机理研究

研究高强度聚焦超声（high intensity focused ultrasound,HIFU）对人膀胱癌细胞的杀伤作用,并探索其作用机理.用不同强度的HIFU处理人膀胱癌细胞T24,用台盼蓝排斥法染色、细胞增殖试验（MTT法）研究HIFU对癌细胞的杀伤和生长抑制作用;流式细胞术检测其对癌细胞周期、凋亡及相关基因表达的影响.HIFU处理后,癌细胞死亡率升高,增殖活性降低,G0/G1期细胞数增加,S期细胞数减少,凋亡指数升高,与对照组比较,差异有显著性意义（P＜0.05）;P53、BCL-2和FAS表达阳性细胞数与对照组比较,无显著性意义（P＞0.05）;HIFU强度为600 W/cm^2时,HSP70表达阳性细胞数升高,与对照组比较差异有显著性意义（P＜0.05）.HIFU对人膀胱癌细胞T24具有明显的杀伤及抑制作用,其机理与抑制DNA合成有关;HIFU具有诱导癌细胞凋亡的作用,其诱导凋亡作用可能与P53、BCL-2和FAS无关.     

尿路上皮癌胚抗原1（UCA1）在人膀胱癌组织及膀胱癌细胞株中特异表达

UCA1（urothelial carcinoma antigen 1）为自主研发的1个尿路上皮癌基因.应用 实时荧光定量PCR检测UCA1 mRNA在2种膀胱癌细胞系、11种非膀胱癌细胞系、18对膀胱 癌组织和配对癌旁正常膀胱组织中的表达,对表达差异进行统计学分析.结果显示, UCA1在2种膀胱癌细胞系中显著高表达,而在其他11种非膀胱癌细胞系中表达水平很低 或者不表达,二者表达差异达14~24 812倍,差异有统计学意义（P<0.001）;在18例膀 胱癌组织中,UCA1的平均表达水平是癌旁正常膀胱组织的12.4倍,表达差异有统计学意 义（P<0.001）. 实时荧光定量PCR使UCA1在膀胱癌细胞系及组织中的特异性高表达得以 量化.实验结果明确了UCA1作为潜在的肿瘤标记物在膀胱癌临床诊断中的意义,为定量 检测尿液UCA1表达并确定诊断膀胱癌的参考值打下基础.     

用组织光学特性鉴别诊断人离体的正常膀胱和膀胱癌组织

研究正常人膀胱和膀胱癌组织在Kube lka-Munk二流模型下对476.5 nm,514.5 nm和808 nm波长的激光的光学特性的差异。采用双积分球系统和Kube lka-Munk二流模型进行测量研究。实验结果表明,正常膀胱和膀胱癌组织在Kube lka-Munk二流模型下对476.5 nm,514.5 nm和808 nm波长的每一个波长的激光的吸收、散射、总衰减、有效衰减系数都有非常显著性的差异(P<0.01)。膀胱癌组织对476.5 nm,514.5 nm和808nm波长的激光的吸收系数明显地较正常膀胱组织对相应波长的激光的吸收系数要大(P<0.01),膀胱癌组织对476.5 nm和514.5 nm波长的激光的散射系数明显地较正常膀胱组织对相应波长的激光的散射系数要小(P<0.01),而膀胱癌组织对808 nm波长的激光的散射系数明显地较正常膀胱组织对同一波长的激光的散射系数要大(P<0.01)。膀胱癌组织对476.5 nm,514.5 nm和808 nm波长的激光的总衰减系数明显地较正常膀胱组织对相应波长的激光的总衰减系数要大(P<0.01),膀胱癌组织对476.5 nm,514.5 nm和808 nm波长的激光的有效衰减系数明显地较正常膀胱组织对相应波长的激光的有效衰减系数要大(P<0.01)。提示使用双积分球系统和Kube lka-Munk二流模型来确定离体的正常膀胱组织和膀胱癌组织对476.5 nm,514.5 nm和808nm波长的激光的光学特性的差异鉴别诊断病变的膀胱组织是一个有效的方法。     

Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer

Members of the human epidermal growth factor receptor (HER) family play a significant role in bladder cancer progression and may underlie the development of chemotherapy resistance. Dacomitinib is an irreversible tyrosine kinase inhibitor with structural specificity for the catalytic domains of epidermal growth factor receptor (EGFR), HER2 and HER4 that has exhibited vigorous efficacy against other solid tumors. We evaluated the antitumor activity of dacomitinib in human bladder cancer cell lines expressing varying levels of HER family receptors. These cell lines also were established as bladder cancer xenografts in nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice to assess dacomitinib activity in vivo. Significant cytotoxic and cytostatic effects were noted in cells expressing elevated levels of the dacomitinib target receptors with apoptosis and cell cycle arrest being the predominant mechanisms of antitumor activity. Cells expressing lower levels of HER receptors were much less sensitive to dacomitinib. Interestingly, dacomitinib was more active than either trastuzumab or cetuximab in vitro, and exhibited increased growth inhibition of bladder tumor xenografts compared with lapatinib. Pharmacodynamic effects of dacomitinib included decreased E-cadherin (E-cad) expression, reduction of EGFR and extracellular signal-regulated kinase (ERK) phosphorylation and reduced mitotic count. Dacomitinib also inhibited tumor growth in a chemotherapy-resistant xenograft and, when combined with chemotherapy in a sensitive xenograft, exhibited superior antitumor effects compared with individual treatments. Evaluation in xenograft-bearing mice revealed that this combination was broadly feasible and well tolerated. In conclusion, dacomitinib exhibited pronounced activity both as a single agent and when combined with chemotherapy in human bladder cancer models. Further investigation of dacomitinib in the preclinical and clinical trial settings is being pursued.     

Mechanism of Monoclonal Antibody-Coupled Staphylococcus Superantigen-A Induced Apoptosis in Human Bladder Cancer Cells

To investigate the mechanism of apoptosis induced by BDI-1 monoclonal antibody (MAb) coupled Staphylococcal superantigen-A (SEA) in human bladder cancer cell line BIU-87. Human PBMC (effector cells) mediated cytotoxic killing of BIU-87 cells (target cells) was studied by culturing the BIU-87 cells in the presence of effector cells plus medium after their activation by treatment with SEA-targeted by MAb, SEA alone or vehicle (control). Proliferation and apoptosis of BIU-87 cells was measured after the treatments. Expression of Bax and Bcl-2 and cytokine concentration in co-culture supernatants were detected by Western blot and ELISA, respectively. Proliferation of MAb-targeted SEA BIU-87 cells decreased significantly (P < 0.05) as compared to control and SEA groups. Flow cytometry revealed apoptosis in SEA alone and more prominently in targeted-SEA treated in BIU-87 cells, which is significantly more than in controI cells (P < 0.05). In addition, Western blot analysis indicated that the ratio of Bax/Bcl-2 significantly increased by targeted SEA treatment, even at low concentration, as compared to cells treated with SEA alone or control cells (P < 0.05). However, there were no significant differences in IL-2, TNF-α and IFN-γ levels in the culture medium between SEA and targeted SEA groups, even though they are several folds higher than in control cells. SEA targeting by MAb significantly increases apoptosis in BIU-87 cells, possibly through the up-regulation of proapoptotic protein Bax and down regulation of antiapoptotic protein, Bcl-2.     

Genotoxic stress in plants: shedding light on DNA damage, repair and DNA repair helicases

Plant cells are constantly exposed to environmental agents and endogenous processes that inflict damage to DNA and cause genotoxic stress, which can reduce plant genome stability, growth and productivity. Plants are most affected by solar UV-B radiation, which damage the DNA by inducing the formation of two main UV photoproducts such as cyclobutane pyrimidine dimers (CPDs) and pyrimidine (6-4) pyrimidone photoproducts (6-4PPs). Reactive oxygen species (ROS) are also generated extra- or intra-cellularly, which constitute yet another source of genotoxic stress. As a result of this stress, the cellular DNA-damage responses (DDR) are activated, which transiently arrest the cell cycle and allow cells to repair DNA before proceeding into mitosis. DDR requires the activation of Ataxia telangiectasia-mutated (ATM) and Rad3-related (ATR) genes, which regulate the cell cycle and transmit the damage signals to downstream effectors of cell-cycle progression. Since genomic protection and stability are fundamental to ensure and sustain plant diversity and productivity, therefore, repair of DNA damages is essential. In plants the bulky DNA lesions, CPDs and 6-4PPs, are repaired by a simple and error-free mechanism: photoreactivation, which is a light-dependent mechanism and requires CPD or 6-4PP specific photolyases. In addition to this direct repair process, the plants also have sophisticated light-independent general repair mechanisms, such as the nucleotide excision repair (NER) and base excision repair (BER). The completed plant genome sequences reveal that most of the genes involved in NER and BER are present in higher plants, which suggests that the network of in-built DNA-damage repair mechanisms is conserved. This article describes the insight underlying the DNA damage and repair pathways in plants. The comet assay to measure the DNA damage and the role of DNA repair helicases such as XPD and XPB are also covered.     

Phosphorylation: Implications in Cancer

Post translational modifications (PTMs) are involved in variety of cellular activities and phosphorylation is one of the most extensively studied PTM, which regulates a number of cellular functions like cell growth, differentiation, apoptosis and cell signaling in healthy condition. However, alterations in phosphorylation pathways result in serious outcomes in the form of diseases, especially cancer. Many signalling pathways including Tyrosine kinase, MAP kinase, Cadherin–catenin complex, Cyclin-dependent kinase etc. are major players of the cell cycle and deregulation in their phosphorylation-dephosphorylation cascade has been shown to be manifested in the form of various types of cancers. Tyrosine kinase family encompasses the greatest number of oncoproteins. MAPK cascade has an importance role in cancer growth and progression. Bcl-2 family proteins serve either proapoptotic or antiapoptotic function. Cadherin–catenin complex regulates cell adhesion properties and cyclins are the key regulators of cell cycle. Altered phosphorylations in any of the above pathways are strongly associated with cancer, at the same time they serve as the potential tergets for drug development against cancer. Drugs targeting tyrosine kinase are potent anticancer drugs. Inhibitors of MEK, PI3K and ERK signalling pathways are undergoing clinical trials. Thus, drugs targeting phosphorylation pathways represent a promising area for cancer therapy.     

聚焦膀胱癌治疗药物

膀胱癌是发生在膀胱黏膜上的泌尿系统常见恶性肿瘤,为全球十大最常见实体瘤之一,特别是在西方国家,其发病率随年龄增长而 增加。重点综述针对膀胱癌的预防、治疗以及各类在研治疗药物与治疗靶标。     

免疫重建荷人膀胱癌-SCID鼠模型的建立

目的：探讨建立稳定的荷人膀胱癌SCID 鼠人化复合模型的方法,为在人免疫重建荷人膀胱肿瘤SCID 鼠模型检测重组BCG 的免疫刺激和免疫保护中打下基础。方法：经SCID 鼠腹腔内注射人PBL、皮下接种RT4 膀胱癌细胞,于接种后4 周检测SCID 鼠体内人免疫细咆水平（IgG 和CD^3＋、CD^4＋、CD^8＋ T 细胞）及脾脏重量,观察皮下成瘤潜伏期及成瘤率。结果：模型组100％成瘤,病理类型为移行细胞癌;检测SCID 鼠血中人IgG 均一定水平存在,与对照组间差异有统计学意义（P〈0.01）;人CD^3＋、CD^4＋、CD^8＋T 细胞在鼠血及脾中均有表达,而对照组均未检出（P〈0.05）;4 周鼠脾重平均（178.9± 45.2）mg。较对照组（40.6± 14.8）mg 差异有统计学意义（P〈0.01）。结论：采用腹腔注射人PBL、皮下接种RT4膀胱癌细胞的方法可以有效地建立人化荷人膀胱癌SCID 鼠模型,较好地模拟人浸润性膀胱癌体内生物学特性,是膀胱癌免疫基因治疗的较理想模型。     

人组织激肽释放酶4在激素依赖性肿瘤中的研究进展

人组织激肽释放酶基因家族由KLK1-KLK15构成,编码一组丝氨酸蛋白酶。研究发现KLK基因家族涉及癌细胞的多种生物学功能,且其表达受类固醇激素的调节。人组织激肽释放酶4是丝氨酸蛋白酶家族的一个成员,在多种激素依赖性肿瘤如卵巢癌、前列腺癌、乳腺癌、子宫内膜癌中高表达,且表达量受雌激素、孕激素、雄激素不同程度的调节。近年来很多文献报道人组织激肽释放酶4涉及癌细胞的增殖、上皮间质转化及细胞外基质的降解等过程,可能促进了肿瘤的发生、发展,且与激素依赖性肿瘤的预后不良有关。这些研究显示人组织激肽释放酶4与激素依赖性肿瘤关系密切,是其潜在的肿瘤标记物和治疗靶点,随着研究的进一步深入,有望应用于激素依赖性肿瘤的早期诊断、病程监测和治疗。     

LOXL4mRNA在膀胱癌中的表达及意义

膀胱癌是泌尿生殖系统最常见的恶性肿瘤,但其发生、发展的机制不清楚.通过采用逆转录聚合酶链反应(RT-PCR)方法检测58例膀胱癌组织、12例时照膀胱组织LOXL4(lysyl oxidase-like protein 4)mRNA的表达及其与临床分期、病理分级的关系.研究发现,58例膀胱癌组织中,LOXIA mRNA阳性表达率为24.1%(14/58),对照膀胱正常组织中LOXL4 mRNA阳性表达率为100%(12/12),膀胱癌组LOXL4 mRNA阳性表达率明显低于对照组(P<0.05).在膀胱癌组织不同临床分期中,Ta～1期阳性表达率为40%(10/25),T2～4期阳性表达率为12.1%(4/33),T2-4期膀胱癌组LOXL4 mRNA阳性表达率低于Ta～1期膀胱癌(P<0.05).不同病理分级膀胱癌组织中,G1阳性表达率为42.9%(9/21),G2～3阳性表达率为13.5%(5,37),G2～3膀胱癌组LOXIA mRNA阳性表达率低于G1膀胱癌(P<0.05).结果表明膀胱癌组LOXL4 mRNA表达水平明显低于正常对照组,LOXL4 mRNA的表达与膀胱癌的临床分期和病理分级呈负相关.提示LOXL4失表达、低表达可能是膀胱癌发生、发展的关键因素之一.